GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Debt-to-EBITDA

Arch Biopartners (TSXV:ARCH) Debt-to-EBITDA : -1.81 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arch Biopartners's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$4.54 Mil. Arch Biopartners's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.50 Mil. Arch Biopartners's annualized EBITDA for the quarter that ended in Dec. 2023 was C$-2.78 Mil. Arch Biopartners's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.81.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Arch Biopartners's Debt-to-EBITDA or its related term are showing as below:

TSXV:ARCH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.79   Med: -0.76   Max: -0.19
Current: -3.2

During the past 13 years, the highest Debt-to-EBITDA Ratio of Arch Biopartners was -0.19. The lowest was -5.79. And the median was -0.76.

TSXV:ARCH's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs TSXV:ARCH: -3.20

Arch Biopartners Debt-to-EBITDA Historical Data

The historical data trend for Arch Biopartners's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Debt-to-EBITDA Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.46 -0.76 -5.79 -4.02 -1.69

Arch Biopartners Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -1.66 -3.58 3.48 -1.81

Competitive Comparison of Arch Biopartners's Debt-to-EBITDA

For the Biotechnology subindustry, Arch Biopartners's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Debt-to-EBITDA falls into.



Arch Biopartners Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Arch Biopartners's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.312 + 0.704) / -2.968
=-1.69

Arch Biopartners's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.537 + 0.5) / -2.78
=-1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Arch Biopartners  (TSXV:ARCH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Arch Biopartners Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners (TSXV:ARCH) Business Description

Traded in Other Exchanges
N/A
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.